Loading
NASDAQHealthcareBiotechnology
Latest quote
$28.02
+$0.16 · +0.57%
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Previous close
$28.02
+$0.16 · +0.57%
Pre-market
$27.81
−$0.21 · -0.75%
Sep 8, 5:15 AM ET
Regular session · ET · Market data may be delayed.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Day range
Current $28.02
52-week range
Current $28.02
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
91
Deep Value
Sentiment
80
Bullish
Risk
28
Moderate Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Day range
Current $28.02
52-week range
Current $28.02
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.07B USD | 957.8M USD | 726.44M USD | 517.24M USD | 484.15M USD |
| Cost of goods sold | 89M USD | 81.84M USD | 45.73M USD | 10.17M USD | 19.14M USD |
| Gross profit | 982.51M USD | 875.96M USD | 680.71M USD | 507.07M USD | 465M USD |
| Research and development | 328.8M USD | 303.25M USD | 351.62M USD | 361.58M USD | 239.42M USD |
| Selling, general, and administrative | 548.89M USD | 488.43M USD | 402.47M USD | 369.09M USD | 396.03M USD |
| Operating expenses | 877.7M USD | 645.16M USD | 754.09M USD | 730.67M USD | 635.44M USD |
| Interest income | 31.72M USD | 25.46M USD | 17.23M USD | 6.61M USD | 591K USD |
| Depreciation and amortization | 11.76M USD | 15.88M USD | 5.55M USD | 2.03M USD | 3.34M USD |
| Operating income | 104.81M USD | 230.79M USD | −73.38M USD | −223.6M USD | −170.44M USD |
| Net income | 391M USD | 226.45M USD | −61.29M USD | −215.98M USD | −167.87M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR223.52M0.20%109.96B USD0.06%$145.34+0.37%
State Street SPDR S&P Biotech ETFXBI117.85M1.03%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI105.95M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM92.09M0.11%80.51B USD0.19%$296.01+0.28%
Vanguard Morningstar Small-Cap ETFVB76.35M0.04%183.4B USD0.03%$300.01+0.05%
Vanguard Morningstar Small-Cap Growth ETFVBK44.31M0.10%43.8B USD0.05%$349.44+0.01%
Vanguard Extended Market ETFVXF37.83M0.04%93.7B USD0.05%$242.66+0.14%
iShares Biotechnology ETFIBB35.53M0.33%10.73B USD0.44%$211.92-0.88%iShares Core S&P Small-Cap ETFIJRState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
